表紙
市場調査レポート

医療機器産業および市場の展望

Medical Devices Industry and Market Prospects 2013-2023

発行 Visiongain Ltd 商品コード 250463
出版日 ページ情報 英文 181 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=136.36円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医療機器産業および市場の展望 Medical Devices Industry and Market Prospects 2013-2023
出版日: 2013年10月23日 ページ情報: 英文 181 Pages
概要

世界の医療機器市場は、2017年に3,980億米ドルの規模に達し、2023年までさらに拡大していくと予測されています。

当レポートでは、世界の医療機器産業および市場の展望について調査分析し、医療機器全体と心臓・胸部外科手術用デバイス、神経系デバイスの市場規模実績・予測、主要製品の分析、パイプラインの分析、市場影響因子の分析、専門家へのインタビューなどをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 イントロダクション:医療機器産業

  • 医療機器の分類
    • 米国の分類システム
    • EUの分類システム
  • 医療機器の法規制
    • 米国の承認・法規制制度
    • EUの承認・法規制制度
  • 冠動脈疾患・冠状動脈ステント
    • 地金ステント
    • 薬物溶出ステント(DES)
    • DESに利用される薬剤
  • 神経調節
    • 慢性的疼痛・脊髄刺激
    • パーキンソン病・深部脳刺激

第3章 世界の医療機器市場

  • 医療機器:市場概要
    • 医療機器市場の規模
    • 医療機器:企業別収益分析
  • 世界の医療機器市場予測
  • 世界の医療機器市場予測
  • 地域の医療機器市場予測
    • 米国・欧州・日本
    • 中国・インド
    • ロシア・ブラジル
    • 欧州5ヶ国
  • 変化する市場シェア:地域別

第4章 医療機器市場への影響因子

  • 医療機器産業および市場のSWOT分析
  • 長所
  • 短所
  • 市場機会
  • 脅威
  • ポーターのファイブフォース分析

第5章 心臓・胸部外科手術用デバイス市場

  • 市場概要
    • 現在の市場
    • 市場予測
  • 薬物溶出冠状動脈ステント市場:分析・予測
    • DES市場の現状
    • DES市場予測
  • 主な冠状動脈ステント製品の分析
    • Biomatrix (Biosensors International)
    • Xience Family of Everolimus-Eluting Stents (Abbott Vascular)
    • Taxus Paclitaxel-Eluting Stent (Boston Scientific)
    • Promus Everolimus-Eluting Stent (Boston Scientific)
    • Endeavor (Medtronic)
  • 冠状動脈ステントのパイプライン
    • Genous Combo (OrbusNeich)
    • Jactax (Boston Scientific)
    • Catania (CeloNova Biosciences)
    • MiStent SES (MiCell Technologies)
    • BioFreedom (Biosensors International)
    • Synergy (Boston Scientific)
  • 生体吸収性薬物溶出ステント
  • DES市場のSWOT分析

第6章 神経系デバイス市場

  • 市場概要
  • 神経系デバイス市場予測
  • 神経刺激市場の分析・予測
    • 神経調節市場の予測
    • SCS市場の予測
    • SCS市場の予測
    • DBS市場の予測
    • DBS市場の予測
    • VNS市場の予測
    • VNS市場の予測
    • その他の神経調節デバイス予測
  • 主要区分の市場シェアの変化
  • 神経調節デバイスのパイプライン
    • NeuroPace
    • Apnex Medical
    • Intelect Medical (Boston Scientific Corporationが買収)
    • CVRx
    • ImThera Medical
    • 肥満症治療用デバイス
  • 神経調節デバイス産業のSWOT分析

第7章 専門家の見解

第8章 結論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Medical devices - your guide to developments, opportunities, and revenues

What does the future hold for medical devices? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and prospects in this market.

Our study gives you revenue forecasts to 2023 at overall world market and national level. There you see financial results, interviews, trends, opportunities, and revenue predictions. You also gain 64 figures, 57 tables and three interviews with authorities in the industry.

Prospects for leading countries shown to 2023

Regulatory, demographic and commercial developments worldwide will influence the market, especially fast-rising demand in emerging markets.

Our analyses show you individual revenue forecasts to 2023 for 11 national markets:

  • US
  • Japan
  • Germany, France, UK, Italy and Spain (EU5 nations)
  • BRIC nations - Brazil, Russia, India, and China

Many commercial opportunities exist in developed and developing countries. Our study explains, assessing progress and prospects.

There you assess the medical device industry's future - hear about developments and find their significance.

Companies and overall 2017 market value - what predicted revenue?

Our report predicts the world market for medical devices will reach $398bn in 2017 and expand further to 2023.

Our work shows you which technologies and organisations hold greatest potential.

In particular, you explore these organisations:

  • Johnson and Johnson
  • GE Healthcare
  • Siemens Healthcare
  • Medtronic
  • Baxter International
  • Philips Healthcare
  • Roche
  • Abbott Laboratories
  • Stryker Corporation
  • Becton, Dickinson & Co.

In general, a company profile gives you the following information:

  • Discussion of a company's activities and outlook
  • Recent financial results
  • Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations
  • Medical device revenue forecasts to 2023

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Prospects for submarkets and products

In addition to analyses of the overall world market, you see revenue forecasting for two important medical device submarkets:

  • Cardiology Devices
  • Neurology Devices

That investigation also discusses sectors within those submarkets. You discover revenue forecasts to 2023 for the following sectors:

  • The drug eluting stents market
  • Neuromodulation devices (including SCS, DBS and VNS markets).

See how and why those sectors can prosper. You see prospects for established and emerging technologies and competition.

Issues affecting the manufacturing and selling of medical devices

In addition, our report discusses issues and events affecting that industry and market from 2013, including these:

  • The medical device excise tax - hampering innovation?
  • Strong government support across major international markets - driving growth
  • Market driven by an aging population
  • Market susceptibility to economic pressures
  • International expansion - targeting emerging national markets
  • Comparative effectiveness research as an added expense
  • Large number of participating companies - increasing rivalry among competitors

You see discussions of technological, commercial and economic matters, with emphasis on organisations competing in the industry.

Ways Medical Devices Industry and Market Prospects 2013-2023 helps you

In summary, our report gives you the following knowledge:

  • Revenues to 2023 for the overall world market - discover that industry's prospects, finding promising areas for investments and revenues
  • Assess 11 leading companies, and others, discovering activities and outlooks
  • Market forecasting to 2023 for the US, Japan, leading EU countries (Germany, France, the UK, Italy and Spain), India, China, Brazil and Russia
  • Prospects for cardiology and neurology devices to 2023
  • Competition and opportunities - see what affects the medical devices industry, learning what shapes its future, esp. prospects for sustaining and developing business
  • Opinions from our survey, seeing interviews with industry authorities.

Information found nowhere else

That work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.

Avoid falling behind in knowledge or missing opportunities with our report. See how you could benefit your research, analyses, and decisions. Also find out how you can save time and gain recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for medical devices. You find data, trends and predictions there. Please order your report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

  • 1.1. Industry Highlights
  • 1.2. Overview of the Report Content
  • 1.3. Research and Analysis Methods
  • 1.4. Glossary of Terms Related to Medical Devices

2. An Introduction to the Medical Device Industry

  • 2.1. Classifying Medical Devices
    • 2.1.1. The US Medical Devices Classification System
    • 2.1.2. The EU Medical Devices Classification System
  • 2.2. Regulation of Medical Devices
    • 2.2.1. The US Approval and Regulation System
    • 2.2.2. The EU Approval and Regulation System
      • 2.2.2.1. Post-marketing Surveillance in the EU
  • 2.3. Coronary Artery Disease and Coronary Stents
    • 2.3.1. Bare Metal Stents
    • 2.3.2. Drug Eluting Stents (DES)
    • 2.3.3. Drugs Used in DES
      • 2.3.3.1. Sirolimus: The first drug to be used on a DES
      • 2.3.3.2. Everolimus
      • 2.3.3.3. Zotarolimus
      • 2.3.3.4. Paclitaxel: the only non-sirolimus deravative In the US market
  • 2.4. Neuromodulation
    • 2.4.1. Chronic Pain and Spinal Cord Stimulation
    • 2.4.2. Parkinson's Disease and Deep Brain Stimulation
      • 2.4.2.1. Parkinson's Disease
      • 2.4.2.2. Deep Brain Stimulation
      • 2.4.2.3. Epilepsy and Vagus Nerve Stimulation

3. The Global Medical Device Market 2013-2023

  • 3.1. Medical Devices: Market Overview
    • 3.1.1. Size of the Medical Device Market in 2012
    • 3.1.2. Medical Devices: Revenue Analysis by Company, 2012
      • 3.1.2.1. Johnson & Johnson: Largest Market Share in the Medical Device Sector
      • 3.1.2.2. GE Healthcare: Strong Growth in Emerging Markets
      • 3.1.2.3. Siemens Healthcare: Third Largest Medical Device Company in 2012
      • 3.1.2.4. Medtronic: Largest Company Solely Manufacturing Medical Devices
      • 3.1.2.5. Baxter International: Major Player in the Renal Devices Sector
      • 3.1.2.6. Philips Healthcare: Specialist in Medical Imaging Systems
      • 3.1.2.7. Roche: Major Player in the European Medical Device Market
      • 3.1.2.8. Abbott Laboratories: Market Leader in the Coronary DES Sector
      • 3.1.2.9. Stryker Corporation: Strong Growth in Neurovascular Business
      • 3.1.2.10. Becton, Dickinson & Co.
      • 3.1.2.11. Samsung: A New Entry Into The Market
  • 3.2. World Medical Device Market Forecast, 2013-2017
  • 3.3. World Medical Device Market Forecast, 2017-2023
  • 3.4. Regional Medical Device Market Forecast, 2013-2023
    • 3.4.1. US, EU5 and Japan - The Leading Regions in the Medical Device Market
      • 3.4.1.1. The US Market: Represents Over a Third of the Global Market
      • 3.4.1.2. The EU5 Markets: Fiscal Restrictions Affecting Market Growth
      • 3.4.1.3. Japan: The Second Largest National Medical Device Market in the World
    • 3.4.2. The Chinese and Indian Markets
      • 3.4.2.1. China: Double Digit CAGR in 2013-2023
      • 3.4.2.2. India: A Rapidly Growing Medical Device Market
    • 3.4.3. Russia and Brazil: New Power Players in the Medical Device Global Market
      • 3.4.3.1. The Russian Market
      • 3.4.3.2. The Brazilian Market
    • 3.4.4. The EU5 Medical Device Markets
      • 3.4.4.1. Germany: The Biggest Medical Device Market in Europe
      • 3.4.4.2. France: A Rapidly Rising over-65Population
      • 3.4.4.3. UK: An Import-led Market
      • 3.4.4.4. Italy: Decentralisation of Medical Services will Drive Growth
      • 3.4.4.5. Spain: Cost-Containment Measures Impacting Growth
  • 3.5. Changing Market Shares by Region, 2012-2023

4. Issues Affecting the Medical Device Market

  • 4.1. SWOT Analysis of the Medical Device Industry and Market, 2013-2023
  • 4.2. Strengths
    • 4.2.1. Strong Government Support Across Major International Markets
    • 4.2.2. Sustained Market Segmentation
    • 4.2.3. Large Number of Participating Companies
  • 4.3. Weaknesses
    • 4.3.1. The Market is Susceptible to Economic Pressures
    • 4.3.2. Much of the Market Has Reached Maturity
  • 4.4. Opportunities
    • 4.4.1. An Aging Global Population
    • 4.4.2. Personalised Medicine Providing Growth Opportunities
    • 4.4.3. Regulatory Harmonisation Across Major International Markets
    • 4.4.4. Increased Incidence and Prevalence of Many Diseases
    • 4.4.5. Rapid Growth in Emerging Markets
  • 4.5. Threats
    • 4.5.1. Changes to Reimbursement Globally
    • 4.5.2. Comparative Effectiveness Research as an Added Expense
    • 4.5.3. US Medical Device Excise Tax
  • 4.6. Porter's Five Force Analysis of the Medical Device Market
    • 4.6.1. Power of Suppliers: Low
    • 4.6.2. Threat of Substitutes: Low
    • 4.6.3. Rivalry Among Competitors: High
    • 4.6.4. Bargaining Power of Buyers: High
    • 4.6.5. Threat of New Entrants: Low

5. The Cardiology Devices Market 2013-2023

  • 5.1. Cardiology Devices: Market Overview
    • 5.1.1. Cardiology Devices Market in 2012
    • 5.1.2. Cardiology Devices Market Forecast, 2013-2023
  • 5.2. The Drug Eluting Coronary Stent Market: Analysis & Forecast 2013-2023
    • 5.2.1. The DES Market, 2012
    • 5.2.2. The DES Market Forecast, 2013-2017
    • 5.2.3. The DES Market Forecast, 2017-2023
  • 5.3. Leading Coronary Stents: Product Analysis
    • 5.3.1. Biomatrix (Biosensors International)
    • 5.3.2. Xience Family of Everolimus-Eluting Stents (Abbott Vascular)
    • 5.3.3. Taxus Paclitaxel-Eluting Stent (Boston Scientific)
    • 5.3.4. Promus Everolimus-Eluting Stent (Boston Scientific)
    • 5.3.5. Endeavor (Medtronic)
  • 5.4. Coronary Stent Pipeline
    • 5.4.1. Genous Combo (OrbusNeich)
    • 5.4.2. Jactax (Boston Scientific)
    • 5.4.3. Catania (CeloNova Biosciences)
    • 5.4.4. MiStent SES (MiCell Technologies)
    • 5.4.5. BioFreedom (Biosensors International)
    • 5.4.6. Synergy (Boston Scientific)
  • 5.5. SWOT Analysis of the DES Market, 2013-2023
    • 5.5.1. Strengths
      • 5.5.1.1. Competition: A Catalyst for DES Market Growth
      • 5.5.1.2. DES: Proven Effectiveness over BMS
      • 5.5.1.3. Continuous Innovation
        • 5.5.1.3.1. Polyzene-F Coated Stents: Potential Game Changer for the Stent Market?
    • 5.5.2. Weaknesses
      • 5.5.2.1. The Success of DES Compared with Other Treatments
      • 5.5.2.2. The Risk of Stent Thrombosis
    • 5.5.3. Opportunities
      • 5.5.3.1. Rising Incidences of Coronary Artery Disease
      • 5.5.3.2. Dual Antiplatelet Therapy: An Avoidable Expense?
    • 5.5.4. Threats
      • 5.5.4.1. The DES Market is Still Emerging
      • 5.5.4.2. US and Japan DES Markets are Dominated by a Small Number of Companies
      • 5.5.4.3. The Stent May Become Secondary to the Eluted Drug

6. The Neurological Device Market 2013-2023

  • 6.1. Neurological Devices: Market Overview
  • 6.2. Neurological Device Market Forecast, 2013-2023
  • 6.3. Neuromodulation Market Analysis
    • 6.3.1. The Neuromodulation Market Forecast, 2013-2023
    • 6.3.2. SCS Market Forecast, 2013-2017
    • 6.3.3. SCS Market Forecast, 2017-2023
    • 6.3.4. DBS Market Forecast, 2013-2017
    • 6.3.5. DBS Market Forecast, 2017-2023
    • 6.3.6. VNS Market Forecast, 2013-2017
    • 6.3.7. VNS Market Forecast, 2017-2023
    • 6.3.8. Other Neuromodulation Devices Forecast, 2013-2023
  • 6.4. Changing Market Shares of the Leading Neuromodulation Segments
  • 6.5. Neuromodulation Device Pipeline
    • 6.5.1. NeuroPace
    • 6.5.2. Apnex Medical
    • 6.5.3. Intelect Medical (acquired by Boston Scientific Corporation)
    • 6.5.4. CVRx
    • 6.5.5. ImThera Medical
    • 6.5.6. Devices Treating Obesity
      • 6.5.6.1. IntraPace
      • 6.5.6.2. EnteroMedics
      • 6.5.6.3. MetaCure
  • 6.6. SWOT Analysis of the Neuromodulation Device Industry, 2013-2023
    • 6.6.1. Strengths
      • 6.6.1.1. Provides a Safer Alternative
      • 6.6.1.2. Neuromodulation Often Means Less Medication
      • 6.6.1.3. Neuromodulation as a Cost-Effective Treatment Option
    • 6.6.2. Weaknesses
      • 6.6.2.1. Mechanisms are Not Fully Understood
      • 6.6.2.2. Delayed FDA approvals
      • 6.6.2.3. A Few Large Companies Dominate the Market
      • 6.6.2.4. Devices Failing in Clinical Trials
    • 6.6.3. Opportunities
      • 6.6.3.1. Neuromodulation Market Set for Rapid Growth due to Expanding Disease Indications
      • 6.6.3.2. Expansion into Emerging Markets
      • 6.6.3.3. Increasing Prevalence of Neurological Diseases
      • 6.6.3.4. The Potential of Personalised Medicine
    • 6.6.4. Threats
      • 6.6.4.1. Increasing Regulatory and Pricing Scrutiny
      • 6.6.4.2. The Emergence of Stem Cell Therapies
      • 6.6.4.3. SCS Faces Competition from Other Treatment Options

7. Expert Opinion

  • 7.1. Interview with Dr. Simon Thomson, Consultant in Pain medicine and Neuromodulation, and President of the International Neuromodulation Society (INS)
    • 7.1.1. The Fast Growing Neuromodulation Market
    • 7.1.2. Potential Advancements in Neuromodulation Technology
    • 7.1.3. Electro-ceuticals: Possible New Treatment?
    • 7.1.4. Strategies To Tackle Negative Perception of Interventional Devices
    • 7.1.5. Medical Devices Excise Tax: Friend or Foe?
    • 7.1.6. Influencing Market Penetration of Neuromodulation Devices
    • 7.1.7. Neuromodulation Market: Future Projection
  • 7.2. Interview with Dr. Mateusz Zelewski, Chief Executive Officer, MetaCure
    • 7.2.1. Current State of the Gastrostimulation Market
    • 7.2.2. Impact of New Tax Legislations
    • 7.2.3. MetaCure's DIAMOND System: New Model
    • 7.2.4. Changing Perception of Interventional Diabetology
    • 7.2.5. Product Distribution and Potential Collaborations
    • 7.2.6. Future Projection for the Gastrostimulation Sector
  • 7.3. Interview with Spokesperson From Boston Scientific Corporation
    • 7.3.1. Current Perspective on the Medical Devices Industry
    • 7.3.2. Boston Scientific's Position in the DES Market
    • 7.3.3. FDA Approval: An Unnecessarily Long-winded Process?
    • 7.3.4. Boston Scientific's Neuromodulation Market Consolidation and Growth Strategies
    • 7.3.5. Influencing Public Oppinion on Interventional Devices
    • 7.3.6. US Excise Tax: A Restraint to Product Innovation?
    • 7.3.7. The Future of the Medical Devices Market

8. Conclusions

  • 8.1. The Medical Device Industry, 2013-2023
    • 8.1.1. Personalised Medicine: Possible Growth Driver in the Coming Decade
    • 8.1.2. Emerging Markets: Urbanisation-Driven Growth
  • 8.2. The Coronary Stent Market, 2013-2023
  • 8.3. The Neurology Market 2013-2023
    • 8.3.1. Neuromodulation: A Rapidly Growing Sector
    • 8.3.2. New Indications Driving Neuromodulation Market Growth
  • 8.4. Alternative Treatment Options: Potential Restraint on Market Growth

List of Tables

  • Table 2.1: The US Classification of Medical Devices
  • Table 2.2: The EU Classification of Medical Devices
  • Table 3.1: The Medical Devices Market: Revenues ($bn) and Market Shares (%) by Sector, 2012
  • Table 3.2: The Top Medical Device Companies: Revenues ($bn) and Market Shares (%), 2012
  • Table 3.3: Johnson & Johnson Medical Devices and Diagnostics: Revenue ($bn) and Revenue Shares (%) by Franchise, 2012
  • Table 3.4: Johnson & Johnson: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.5: GE Healthcare: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.6: Siemens Healthcare Medical Devices: Revenues ($bn) and Revenue Shares (%) by Region, 2011and 2012
  • Table 3.7: Siemens Healthcare: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.8: Medtronic: Revenues ($bn) and Revenue Shares (%) by Franchise, 2012
  • Table 3.9: Medtronic: Revenues ($bn) and Revenue Shares (%) by Region, 2012
  • Table 3.10: Medtronic: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.11: Baxter International: Revenues ($bn) and Revenue Shares (%) by Business Sector, 2012
  • Table 3.12: Baxter International: Revenues ($bn) and Revenue Shares (%) by Region, 2012
  • Table 3.13: Baxter International: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.14: Philips Healthcare: Revenues ($bn) and Revenue Shares (%) by Sector, 2012
  • Table 3.15: Philips Healthcare Medical Devices: Revenues ($bn) and Revenue Shares (%) by Region, 2012
  • Table 3.16: Philips Healthcare: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.17: Roche Medical Devices and Diagnostics: Revenues ($bn) and Revenue Shares (%) by Sector, 2012
  • Table 3.18: Roche: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.19: Abbott Medical Devices and Diagnostics: Revenues ($bn) and Revenue Shares (%) by Region, 2012
  • Table 3.20: Abbott Laboratories: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.21: Stryker Corporation Medical Devices: Total Revenue Shares (%) by Franchise, 2012
  • Table 3.22: Stryker Corporation: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.23: Becton Dickinson & Co: Medical Devices Revenues ($bn) and Revenue Shares (%) by Sector, 2012
  • Table 3.24: Becton Dickinson & Co: Medical Devices Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 3.25: The Global Medical Device Market: Drivers and Restraints, 2013-2023
  • Table 3.26: The Global Medical Devices Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2012-2017
  • Table 3.27: The Global Medical Devices Market: Revenue Forecast ($bn, AGR%, CAGR%) by Region, 2017-2023
  • Table 3.28: The EU5 Medical Devices Markets: Revenues ($bn) and Market Shares (%) by Country, 2012
  • Table 3.29: The EU5 Medical Devices Markets: Revenue Forecast ($bn, AGR%, CAGR%) by Country, 2012-2017
  • Table 3.30: The EU5 Medical Devices Markets: Revenue Forecast ($bn, AGR%, CAGR%) by Country, 2017-2023
  • Table 3.31: The Medical Device Market: Revenue ($bn) by Region, 2012, 2017 and 2023
  • Table 3.32: The Medical Device Market: Market Shares (%) by Region, 2012, 2017 and 2023
  • Table 4.1: SWOT Analysis for the Medical Device Industry, 2013-2023
  • Table 5.1: Cardiology Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
  • Table 5.2: Cardiology Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
  • Table 5.3: Drug Eluting Stents: Market Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
  • Table 5.4: Drug Eluting Stents: Market Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
  • Table 5.5: Growth Drivers and Restraints for the Drug Eluting Stent Market, 2013-2023
  • Table 5.6: Boston Scientific's Taxus Stent Revenue ($bn) by Region, 2011& 2012
  • Table 5.7: Coronary Stent Development Pipeline, 2013
  • Table 5.8: SWOT Analysis for the DES Market, 2013-2023
  • Table 6.1: Neurological and Neuromodulation Markets: Revenue ($bn) by Sector, 2012
  • Table 6.2: Neurological Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
  • Table 6.3: Neurological Devices: Market Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
  • Table 6.4: Neuromodulation Devices: Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2012-2017
  • Table 6.5: Neuromodulation Devices Revenue Forecast ($bn, AGR%, CAGR%) by Sector, 2017-2023
  • Table 6.6: SCS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
  • Table 6.7: SCS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
  • Table 6.8: DBS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
  • Table 6.9: DBS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
  • Table 6.10: VNS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2017
  • Table 6.11: VNS Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2017-2023
  • Table 6.12: Other Neuromodulation Devices: Revenue Forecast ($bn, AGR%, CAGR%), 2012-2023
  • Table 6.13: Neuromodulation Devices: Market Shares (%) by Sector, 2012-2023
  • Table 6.14: Neuromodulation Devices: Industry Pipeline, 2013
  • Table 6.15: SWOT Analysis of the Neuromodulation Devices Industry, 2013-2023

List of Figures

  • Figure 2.1: The Structure of Sirolimus
  • Figure 2.2: The Structure of Everolimus
  • Figure 2.3: The Structure of Zotarolimus
  • Figure 2.4: The Structure of Paclitaxel
  • Figure 3.1: The Medical Device Market: Market Shares (%) by Sector, 2012
  • Figure 3.2: Johnson & Johnson Medical Devices and Diagnostics: Revenue Shares (%) by Franchise, 2012
  • Figure 3.3: Johnson & Johnson Medical Devices and Diagnostics: Revenue ($bn) by Franchise, 2012
  • Figure 3.4: Johnson & Johnson: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.5: GE Healthcare: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.6: Siemens Healthcare Medical Devices: Revenue Shares (%) by Region, 2012
  • Figure 3.7: Siemens Healthcare Medical Devices: Revenue ($bn) by Region, 2011and 2012
  • Figure 3.8: Siemens Healthcare: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.9: Medtronic: Revenue Shares (%) by Franchise, 2012
  • Figure 3.10: Medtronic: Revenue ($bn) by Region, 2012
  • Figure 3.11: Medtronic: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.12: Baxter International: Revenues ($bn) by Business Sector, 2012
  • Figure 3.13: Baxter International: Revenue Shares (%) by Region, 2012
  • Figure 3.14: Baxter International: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.15: Philips Healthcare Medical Devices: Revenue Shares (%) by Sector, 2012
  • Figure 3.16: Philips Healthcare: Revenues ($bn) by Region, 2012
  • Figure 3.17: Philips Healthcare: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.18: Roche Medical Devices and Diagnostics: Revenue ($bn) by Sector, 2012
  • Figure 3.19: Roche: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.20: Abbott Medical Devices and Diagnostics: Revenue ($bn) by Region, 2012
  • Figure 3.21: Abbott Medical Devices and Diagnostics: Revenue Shares (%) by Region, 2012
  • Figure 3.22: Abbott Laboratories: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.23: Stryker Corporation Medical Devices: Total Revenue Shares (%) by Franchise, 2012
  • Figure 3.24: Stryker Corporation: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.25: Becton Dickinson & Co: Medical Devices Revenue Shares (%) by Sector, 2012
  • Figure 3.26: Becton Dickinson & Co: Medical Devices Revenue Forecast ($bn), 2012-2023
  • Figure 3.27: The Global Medical Devices Market: Revenue Forecast ($bn), 2012-2017
  • Figure 3.28: The Global Medical Devices Market: Revenue Forecast ($bn), 2017-2023
  • Figure 3.29: US, EU5 and Japan Medical Devices Markets: Revenue Forecast ($bn), 2012-2017
  • Figure 3.30: US, EU5 and Japan Medical Devices Markets: Revenue Forecast ($bn), 2017-2023
  • Figure 3.31: China and India: Medical Devices Revenue Forecast ($bn), 2012-2017
  • Figure 3.32: China and India: Medical Devices Revenue Forecast ($bn), 2017-2023
  • Figure 3.33: Brazil and Russia: Medical Devices Revenue Forecast ($bn), 2012-2017
  • Figure 3.34: Brazil and Russia: Medical Devices Revenue Forecast ($bn), 2017-2023
  • Figure 3.35: The EU5 Medical Devices Markets: Market Shares (%) by Country, 2012
  • Figure 3.36: The EU5 Medical Devices Markets: Revenue Forecast ($bn), 2012-2017
  • Figure 3.37: The EU5 Medical Devices Markets: Revenue Forecast ($bn), 2017-2023
  • Figure 3.38: Medical Device Market: Revenue ($bn) by Region, 2013, 2017 and 2023
  • Figure 3.39: The Medical Devices Market: Market Shares (%) by Region, 2012
  • Figure 3.40: The Medical Devices Market: Market Shares (%) by Region, 2017
  • Figure 3.41: The Medical Devices Market: Market Shares (%) by Region, 2023
  • Figure 5.1: Cardiology Devices: Market Revenue Forecast ($bn), 2012-2017
  • Figure 5.2: Cardiology Devices: Market Revenue Forecast ($bn), 2017-2023
  • Figure 5.3: Drug Eluting Stents: Market Revenue Forecast ($bn), 2012-2017
  • Figure 5.4: Drug Eluting Stents: Market Revenue Forecast ($bn), 2017-2023
  • Figure 5.5: Boston Scientific's Taxus Stent Revenue ($bn) by Region, 2011& 2012
  • Figure 6.1: Neurological Devices: Market Revenue Forecast ($bn), 2012-2017
  • Figure 6.2: Neurological Devices: Market Revenue Forecast ($bn), 2017-2023
  • Figure 6.3: Neuromodulation Devices: Revenue Forecast ($bn), 2012-2017
  • Figure 6.4: Neuromodulation Devices: Revenue Forecast ($bn), 2017-2023
  • Figure 6.5: SCS Devices: Revenue Forecast ($bn), 2012-2017
  • Figure 6.6: SCS Devices: Revenue Forecast ($bn), 2017-2023
  • Figure 6.7: DBS Devices: Revenue Forecast ($bn), 2012-2017
  • Figure 6.8: DBS Devices: Revenue Forecast ($bn), 2017-2023
  • Figure 6.9: VNS Devices: Revenue Forecast ($bn), 2012-2017
  • Figure 6.10: VNS Devices: Revenue Forecast ($bn), 2017-2023
  • Figure 6.11: Other Neuromodulation Devices: Revenue Forecast ($bn), 2012-2023
  • Figure 6.12: Neuromodulation Devices: Market Shares (%) by Sector, 2012
  • Figure 6.13: Neuromodulation Devices: Market Shares (%) by Sector, 2017
  • Figure 6.14: Neuromodulation Devices: Market Shares (%) by Sector, 2023

Companies Listed

  • Abbott Laboratories
  • Angiotech Pharmaceuticals
  • Apnex Medical Inc
  • Association of Indian Medical Device Industry (AIMED)
  • Baxter International
  • Becton Dickinson & Co
  • Biosensors International
  • Biotronik SE & Co
  • Boston Scientific
  • Brazilian National Agency for Sanitary Surveillance (ANVISA)
  • Bristol Myers Squibb
  • CeloNova BioSciences Inc
  • Center for Devices and Radiological Health (CDRH) [US]
  • Central Drug Standard Control Organisation (CDSCO) [India]
  • Cerbomed
  • Cerebral Rx
  • China Food and Drug Administration (CFDA)
  • ClearStream Technologies
  • Cochlear Ltd.
  • Conor Medsystems Inc
  • Cordis Corporation
  • CVRx Inc
  • Cyberonics Inc.
  • DePuy Inc
  • Economic Committee for Medical Products [France]
  • ElectroCore
  • EnteroMedics Inc
  • Ethicon Endo-Surgery Inc
  • Eucomed
  • European Commission (EC)
  • Food & Drug Administration (FDA) [US]
  • GE Healthcare
  • Gemeinsame Bundesausschuss (G-BA) [Germany]
  • GlaxoSmithKline (GSK)
  • Global Harmonisation Task Force (GHTF)
  • Guidant Corporation
  • Impulse Dynamics
  • ImThera Medical Inc
  • Insightra Medical
  • Intelect Medical Inc
  • International Medical Device Regulators Forum (IMDRF)
  • International Neuromodulation Society (INS)
  • IntraPace Inc
  • Johnson & Johnson (J&J)
  • JW Medical Systems
  • KangHui Medical
  • Kiestra Lab Automation
  • Labcoat Ltd
  • Lupin Pharmaceuticals Inc
  • Medison Co Ltd
  • Medical Device Regulatory Authority (MDRA) [India]
  • Medtronic Inc
  • MetaCure Inc
  • MiCell Technologies Inc
  • Ministry of Health, Labour, and Welfare (MHLW) [Japan]
  • MIV Therapeutics Inc
  • National Epilepsy Foundation [US]
  • National Institute for Health and Clinical Excellence (NICE) [UK]
  • NeuroPace Inc
  • Northstar Neuroscience Inc
  • Novartis
  • OrbusNeich
  • Ortho-Clinical Diagnostics Inc
  • Patient-Centered Outcomes Research Institute (PCORI) [US]
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Pfizer
  • Philips Healthcare
  • Roszdravnadzor [Russia]
  • Roche
  • Samsung
  • Sanofi-aventis
  • Servizio Sanitario Nazionale (SSN) [Italy]
  • Siemens Healthcare
  • Sistema Unico de Saude (SUS) [Brazil]
  • St Jude Medical
  • St. Michael's Hospital, Toronto, Canada
  • Stryker Corporation
  • Synthes
  • Terumo Medical Corporation
  • Teva Pharmaceutical Industries Ltd
  • Third Wave Technologies Inc
  • Transneuronix Inc
  • Trauson Holding
  • United Nations (UN)
  • United State Patent and Trademark Office (USPTO)
  • UCB Biopharma
  • Vitality Devices
  • World Health Organisation (WHO)
Back to Top